Inactive Instrument

Company Myovant Sciences Ltd.

Equities

MYOV

BMG637AM1024

Biotechnology & Medical Research

Business Summary

Myovant Sciences Ltd is a biopharmaceutical company. The Company is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company's two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It develops Relugolix for the treatment of men with advanced prostate cancer. The Company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.

Number of employees: 579

Managers

Managers TitleAgeSince
Chief Executive Officer 59 21-01-03
Director/Board Member 61 19-12-26
Corporate Officer/Principal 56 -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 61 19-12-26
Chief Executive Officer 59 21-01-03
Director/Board Member 59 22-10-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 97,235,316 46,097,791 ( 47.41 %) 0 47.41 %

Company contact information

Myovant Sciences Ltd.

11-12 St. James?s Square Suite 1, 3rd Floor

SW1Y 4LB, London

+

http://www.myovant.com
address Myovant Sciences Ltd.(MYOV)
  1. Stock Market
  2. Equities
  3. MYOV Stock
  4. Company Myovant Sciences Ltd.